A retrospective study of 50 patients with scirrhous carcinoma of the stomach who had undergone surgery was performed to elucidate whether immunohistochemical overexpression of transforming growth factor-β1 (TGF-β1) could predict the patients’ survival. To evaluate the proliferative activity of the tumor, the proliferating cell nuclear antigen (PCNA) index was used. Expression of TGF-β1 was low in 27 patients and high in 23. Clinicopathological characteristics were not significantly different between the two groups with high and low TGF-β1 expression. Tumors with higher TGF-β1 expression had higher PCNA indices (p = 0.0467, unpaired Student’s t test). The 5-year survival rate was 40.4% for the low TGF-β1 group and 28.7% for the high TGF-β1 group (p = 0.0388, log rank test). By multivariate analysis, pT, residual tumor, and TGF-β1 were the independent prognostic factors. These results suggest that immunohistochemical expression of TGF-β1 is one of the useful predictors for estimating the patients’ survival in scirrhous carcinoma of the stomach particularly of the T3 and T4 stages.

Keywords:
TGF-β1, Gastric carcinoma, Scirrhus, Immunohistochemistry, Proliferating cell nuclear antigen
This content is only available via PDF.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.